Ann: AnteoTech Signs SE Asian Distribution Agreement for EuGeni, page-138

Is there something I am missing?



Early April - ADO enters negotiations for EXCLUSIVE Distribution Agreement (Asia) with Biomed Global
On 28 April ADO announces funds needed to support sales launch. (read provide Distributor with sufficient product to sell)
ADO will have capacity to produce 32 million test strips per annuam commencing 2022 Year (assume calender year)
On 19 July 2021 ADO states it has sufficient test kit capacity to meet immediate demand. (8 mill from Operon for 1 yr)
Exclusive Distribution Agreement is for 12 months ( to determine if ADO can deliver product and Biomed sell).
I asume that Biomed Global has done its homework on ADO and would not want to damage its reputation with an inferior product or Lifescience Partner.

I can accept that a "sale: is not a sale until money is in the bank, but the current sale pipeline status is looking pretty good.
To me the revenue is in the interpretation of the announcement.